Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q3 2026

Q3 2026 biggest moves
  • VTRSVTRS

    Viatris

    Cut 46%

    now 3.0% of portfolio

  • LNTHLNTH

    Lantheus

    Sold out

    was 0.9% of portfolio

  • CHECHE

    Chemed

    6.1× the shares

    now 1.4% of portfolio

  • CELCCELC

    Celcuity

    Added 65%

    now 2.9% of portfolio

45 changes in all

Top Holdings77 positions

Checking export access…
Activity:
RVMD

Revolution Medicines, Inc.

2.1M$436M6.7%$35.80+350.26%
27 qtrssince 2020-Q1
Decreased
0
306.9M$425.6M6.6%——
4 qtrssince 2025-Q4
Unchanged
0
CNC

Centene Corporation

4.9M$304.5M4.7%$46.26+37.88%
28 qtrssince 2019-Q4
Unchanged
0
UTHR

United Therapeutics Corporation

540,598$292.9M4.5%$352.63+57.31%
7 qtrssince 2025-Q1
Increased
67
PRAX

Praxis Precision Medicines, Inc.

963,351$280.6M4.3%$74.95+300.83%
7 qtrssince 2025-Q1
Unchanged
0
200M$257.8M4.0%——
2 qtrssince 2026-Q2
Unchanged
0
GMAB
GMAB
ADR

Genmab A/S

6.9M$244.9M3.8%$27.24+85.75%
3 qtrssince 2026-Q1
Unchanged
0
200M$205.5M3.2%——
3 qtrssince 2026-Q1
Unchanged
0
VTRS

Viatris Inc.

10.9M$193.8M3.0%$11.15+76.04%
24 qtrssince 2020-Q4
Decreased
0
COGT

Cogent Biosciences, Inc.

6M$190.7M3.0%$15.76+69.53%
24 qtrssince 2020-Q4
Increased
62
CELC

Celcuity Inc.

2.4M$190.7M2.9%$78.72-32.23%
5 qtrssince 2025-Q3
Increased
77
LEGN
LEGN
ADR

Legend Biotech Corporation

8.1M$161.9M2.5%$25.75-40.78%
8 qtrssince 2024-Q4
Unchanged
0
VERA

Vera Therapeutics, Inc.

4.3M$140.1M2.2%$28.11-9.48%
7 qtrssince 2025-Q1
Increased
57
TNGX

Tango Therapeutics, Inc.

5.2M$129.2M2.0%$15.01+44.78%
4 qtrssince 2025-Q4
Increased
58
BCRX

BioCryst Pharmaceuticals, Inc.

15.5M$129M2.0%$7.45-3.11%
15 qtrssince 2023-Q1
Increased
49
BKD

Brookdale Senior Living Inc.

11.6M$126M1.9%$4.41+100.88%
28 qtrssince 2019-Q4
Unchanged
0
BMRN

BioMarin Pharmaceutical Inc.

2M$121.5M1.9%$57.86+4.40%
3 qtrssince 2026-Q1
Increased
66
IONS

Ionis Pharmaceuticals, Inc.

2.7M$118.8M1.8%$60.10-55.78%
5 qtrssince 2025-Q3
Increased
61
LRMR

Larimar Therapeutics, Inc.

35.6M$113.8M1.8%$5.44-42.29%
26 qtrssince 2020-Q2
Unchanged
0
NAMS

NewAmsterdam Pharma Company N.V.

4.3M$103.5M1.6%$23.84-22.78%
11 qtrssince 2024-Q1
Decreased
0
$6.5B
AUM
77
Positions
Q3 2026
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2025-Q2$5,509,809,2648.78675652937%
2025-Q3$6,550,740,15118.8923216236%
2025-Q4$7,830,165,97019.5310116034%
2026-Q1$8,476,379,7168.25287418525%
2026-Q2$9,586,027,94413.0910632272%
2026-Q3$6,465,822,053-32.5495179988%
Activity profile
$ moved · Q3'26
New7%Increased10%Decreased13%Exited70%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.3 years
<1Q5%1-4Q6%1-2Y3%2Y+86%

Deerfield Management Company, L.P. manages $6.5B across 77 positions as of Q3 2026. Top holdings: RVMD (6.7%), BROOKDALE SR LIVING INC (6.6%), CNC (4.7%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$6B
RVMD6.74%
BROOKDALE SR6.58%
CNC4.71%
UTHR4.53%
PRAX4.34%
REVOLUTION M3.99%
GMAB3.79%
ARROWHEAD PH3.18%
VTRS3.00%
COGT2.95%
Other2.95%

Portfolio allocation by GICS sector

Sectors1
Healthcare100.00%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used